These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21855668)

  • 1. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.
    Niziolek PJ; Farmer TL; Cui Y; Turner CH; Warman ML; Robling AG
    Bone; 2011 Nov; 49(5):1010-9. PubMed ID: 21855668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
    Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
    J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Lrp5 HBM-causing mutations in Cathepsin-K expressing cells alters bone metabolism.
    Kang KS; Hong JM; Horan DJ; Lim KE; Bullock WA; Bruzzaniti A; Hann S; Warman ML; Robling AG
    Bone; 2019 Mar; 120():166-175. PubMed ID: 30409757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner.
    Niziolek PJ; Warman ML; Robling AG
    Bone; 2012 Sep; 51(3):459-65. PubMed ID: 22750014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases.
    Gregson CL; Wheeler L; Hardcastle SA; Appleton LH; Addison KA; Brugmans M; Clark GR; Ward KA; Paggiosi M; Stone M; Thomas J; Agarwal R; Poole KE; McCloskey E; Fraser WD; Williams E; Bullock AN; Davey Smith G; Brown MA; Tobias JH; Duncan EL
    J Bone Miner Res; 2016 Mar; 31(3):640-9. PubMed ID: 26348019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
    Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ
    Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of overexpression of Lrp5 on orthodontic tooth movement.
    Holland R; Bain C; Alrasheed RS; Robling AG; Utreja A
    Orthod Craniofac Res; 2021 Aug; 24(3):430-437. PubMed ID: 33326696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High bone mass in mice expressing a mutant LRP5 gene.
    Babij P; Zhao W; Small C; Kharode Y; Yaworsky PJ; Bouxsein ML; Reddy PS; Bodine PV; Robinson JA; Bhat B; Marzolf J; Moran RA; Bex F
    J Bone Miner Res; 2003 Jun; 18(6):960-74. PubMed ID: 12817748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5.
    Lee GS; Simpson C; Sun BH; Yao C; Foer D; Sullivan B; Matthes S; Alenina N; Belsky J; Bader M; Insogna KL
    J Bone Miner Res; 2014 Apr; 29(4):976-81. PubMed ID: 24038240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.
    Niziolek PJ; Bullock W; Warman ML; Robling AG
    PLoS One; 2015; 10(11):e0140775. PubMed ID: 26554834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
    J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.
    Simpson CA; Foer D; Lee GS; Bihuniak J; Sun B; Sullivan R; Belsky J; Insogna KL
    Osteoporos Int; 2014 Oct; 25(10):2383-8. PubMed ID: 24927689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone biomechanical properties in LRP5 mutant mice.
    Akhter MP; Wells DJ; Short SJ; Cullen DM; Johnson ML; Haynatzki GR; Babij P; Allen KM; Yaworsky PJ; Bex F; Recker RR
    Bone; 2004 Jul; 35(1):162-9. PubMed ID: 15207752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes.
    Leanza G; Fontana F; Lee SY; Remedi MS; Schott C; Ferron M; Hamilton-Hall M; Alippe Y; Strollo R; Napoli N; Civitelli R
    J Bone Miner Res; 2021 Jul; 36(7):1403-1415. PubMed ID: 33831261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration.
    Turkkahraman H; Flanagan S; Zhu T; Bellido TM; Yuan X
    J Periodontal Res; 2023 Aug; 58(4):723-732. PubMed ID: 37128744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.